PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Ifosfamide

Drugs in development · updated 30 October 2026

Ifosfamide: clinical trials and development status

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Ifosfamide is in 56 active clinical trials (recruiting or ongoing, phases I–III) for 56 diseases. The most advanced phase is III.

56Active trials
IIIMost advanced phase
56Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Ifosfamide and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 56 diseases.

DiseaseMost advanced phaseActive trialsReference trial
SarcomaIII10NCT03805022
Diffuse large B-cell lymphomaIII9NCT06792253
B-cell lymphomaIII4NCT06230224
OsteosarcomaIII4NCT00470223
Precursor lymphoblastic lymphoma/leukemiaIII4NCT03007147
Burkitt lymphomaIII3NCT03007147
Ewing sarcomaIII3NCT02306161
ChoriocarcinomaIII2NCT02375204
Germ cell and embryonal neoplasmsIII2NCT02375204
Non-Hodgkin lymphomaIII2NCT06230224
Precursor T-cell lymphoblastic leukemiaIII2NCT02112916
TeratomaIII2NCT02375204
Acute biphenotypic leukaemiaIII1NCT03007147
Endodermal sinus tumorIII1NCT02375204
GerminomaIII1NCT02375204
Nonseminomatous germ cell tumorIII1NCT02375204
Penile neoplasmIII1NCT02305654
Pleuropulmonary blastomaIII1NCT06647953
SeminomaIII1NCT02375204
FibrosarcomaII3NCT06849986
HemangiosarcomaII3NCT06849986
LeiomyosarcomaII3NCT06849986
LiposarcomaII3NCT06849986
NeurofibrosarcomaII3NCT06849986
RhabdomyosarcomaII3NCT01871766
Desmoplastic small-round-cell tumorII2NCT06849986
Follicular lymphomaII2NCT02393157
Hodgkin lymphomaII2NCT03418038
LymphomaII2NCT02106988
NeuroblastomaII2NCT06528496

Everything on Ifosfamide

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch